Interferon beta-1a: Clinical Trials

34 trials of Interferon beta-1a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 5 terminated, 2 active not recruiting, 1 recruiting. 34 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 334Completed 24, Terminated 5, Active not recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 22Completed 2

Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
Remdesivir, Acalabrutinib, Interferon beta-1a - Covid19
Phase 3UnknownThe University of The West Indies1002021-06-012021-05-13
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
Interferon beta-1a, Placebo, Remdesivir - COVID-19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)9692020-08-052022-03-14
Trial of Treatments for COVID-19 in Hospitalized Adults
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A - Corona Virus Infection
Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France15522020-03-222026-07-08
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
BIIB017 (peginterferon beta-1a), Interferon beta type 1a - Multiple Sclerosis, Relapsing-Remitting
Phase 3Active not recruitingBiogen1522019-10-182026-09-24
Study of Evobrutinib in Participants With RMS
Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis
Phase 3TerminatedEMD Serono Research & Development Institute, Inc.12019-09-102021-08-05
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis
Phase 3TerminatedEMD Serono Research & Development Institute, Inc.32019-08-262021-08-05
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
BCD-054 180 mcg, Avonex®, BCD-054 240 mcg - Multiple Sclerosis, Relapsing-Remitting
Phase 2 / Phase 3CompletedBiocad3992017-08-102021-09-08
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic)
Phase 3RecruitingUMC Utrecht200002016-04-112026-11-04
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
Interferon beta-1a, Placebo - Respiratory Distress Syndrome, Adult
Phase 3TerminatedFaron Pharmaceuticals Ltd3012015-12-232020-03-30
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
BCD-033 (interferon beta 1a), Rebif (interferon beta 1a), Placebo - Multiple Sclerosis
Phase 2 / Phase 3CompletedBiocad1632015-02-122023-02-17
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Ozanimod, Interferon beta-1a, Placebo to ozanimod - Multiple Sclerosis
Phase 3CompletedCelgene13462014-12-032020-11-25
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
dimethyl fumarate, Interferon β-1a - Relapsing-Remitting Multiple Sclerosis
Phase 3CompletedBiogen1562014-08-282026-05-19
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis
Phase 3WithdrawnTeva Branded Pharmaceutical Products R&D, Inc.2014-01-012021-11-09
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Ozanimod, Ozanimod placebo, Interferon beta-1a - Relapsing Multiple Sclerosis
Phase 3CompletedCelgene13202013-12-032021-02-11
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Interferon beta-1a, Fingolimod, Placebo capsule - Multiple Sclerosis
Phase 3Active not recruitingNovartis Pharmaceuticals2402013-07-262026-08-10
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis
Phase 3CompletedHoffmann-La Roche8352011-09-202024-03-08
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis
Phase 3CompletedHoffmann-La Roche8212011-08-312024-03-04
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
Interferon beta 1a, Mitoxantrone - Multiple Sclerosis
Phase 3CompletedRennes University Hospital352010-12-062023-03-29
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a - Relapsing-Remitting Multiple Sclerosis
Phase 3CompletedBiogen18412010-05-012016-07-11
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
Avonex - Multiple Sclerosis
Phase 3CompletedBiogen602010-04-012013-09-16

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Multiple Sclerosis (15)  ·  Multiple Sclerosis, Relapsing-Remitting (13)  ·  COVID-19 (4)  ·  Pneumonia (2)  ·  Autoimmune Diseases (1)  ·  Community-Acquired Pneumonia (1)  ·  Coronavirus Infections (1)  ·  Hepatitis C (1)  ·  Influenza, Human (1)  ·  Lung Diseases (1)  ·  Respiratory Distress Syndrome (1)  ·  Respiratory Insufficiency (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Infections (1)  ·  Thinness (1)

Sponsors

Biogen (8)  ·  Merck KGaA, Darmstadt, Germany (3)  ·  Biocad (2)  ·  Celgene (2)  ·  EMD Serono (2)  ·  EMD Serono Research & Development Institute, Inc. (2)  ·  Genzyme, a Sanofi Company (2)  ·  Hoffmann-La Roche (2)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (2)  ·  Faron Pharmaceuticals Ltd (1)  ·  Fred Lublin (1)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Novartis Pharmaceuticals (1)  ·  Rennes University Hospital (1)

Countries

United States (19)  ·  Germany (17)  ·  France (16)  ·  Spain (16)  ·  Canada (15)  ·  Czechia (15)  ·  Italy (15)  ·  Poland (14)  ·  Russia (14)  ·  Belgium (12)  ·  Serbia (12)  ·  United Kingdom (12)  ·  Croatia (11)  ·  Bulgaria (10)  ·  Australia (9)

Top investigators

Bettina M. Stubinski, MD (1)  ·  Colin McArthur, Dr (1)  ·  Derek Angus, Prof (1)  ·  Florence Ader, MD (1)  ·  Fred Lublin, MD (1)  ·  Geoffrey Bellingan, MD (1)  ·  Gordon Francis, M.D. (1)  ·  James Sheffiled, MD (1)

Results publications

PMID 34473343, PMID 36163349, PMID 37652990, PMID 27590291, PMID 28002679, PMID 30144037, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32511687, PMID 32690791, PMID 32710396, PMID 33414927, PMID 33724637, PMID 34035833, PMID 34350582, PMID 34882037, PMID 34904871, PMID 35672926, PMID 36619856, PMID 36695483, PMID 36792367, PMID 37148240, PMID 37272540, PMID 37745914, PMID 39290861, PMID 39935588, PMID 39965438, PMID 40258203, PMID 40462564, PMID 40554392, PMID 40629721, PMID 42832215, PMID 17654600, PMID 21999176, PMID 22146409, PMID 23424159, PMID 24126064, PMID 24292999, PMID 24413638, PMID 24686106, PMID 25111080, PMID 26000222, PMID 26444729, PMID 27251051, PMID 28039317, PMID 28104250, PMID 28485186, PMID 28835401, PMID 28984179

NIH funding

2018 (3), 2014 (2), 2023 (2), 2004 (1), 2008 (1), 2009 (1), 2015 (1), U01NS045719 (1)